Vivos director granted 12,000 options at $0.18

Vivos Therapeutics, Inc. (VVOS) reported that director Gregg C. Johnson received a grant of 12,000 stock options on September 14, 2026, each with an exercise price of $0.18 per share and a 10-year term.

Rhea-AI Filing Summary

Vivos Therapeutics, Inc. (VVOS) reported that director Gregg C. Johnson received a grant of 12,000 stock options on September 14, 2026, each with an exercise price of $0.18 per share and a 10-year term. One-half of the options vested immediately, one-fourth will vest on September 30, 2026, and one-fourth will vest on December 31, 2026. After this grant, he holds 12,000 options directly and 3,997 shares of common stock indirectly through an affiliated limited partnership.

Insider Trade Summary

Grant/Award: 12,000 shares

Grant/Award 2 txns

Insider JOHNSON GREGG C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy) F2	12,000	$0.00	$0.00
holding	Common Stock F1	--	--	--

Holdings After Transaction: Stock Options (Right to Buy) — 12,000 contracts (Direct); Common Stock — 3,997 shares (Indirect, See footnote)

Footnotes (2)

1. F1. Shares held by Spite Family Holdings LP, an affiliate of the Reporting Person.
2. F2. On September 14, 2026 (the "Grant Date"), the Reporting Person received a grant of 12,000 stock options from the Issuer. One-half vested immediately (and the earliest possible exercise date in Table II relates to this tranche), one-fourth will vest on September 30, 2026 and one-fourth will vest on December 31, 2026. The options are exercisable for a period of 10 years from the Grant Date.

Key Figures

Stock options granted: 12,000 options Exercise price: $0.18 per share Option term: 10 years +4 more

7 metrics

Stock options granted 12,000 options Grant to director Gregg C. Johnson on September 14, 2026

Exercise price $0.18 per share Exercise price of the 12,000 stock options granted

Option term 10 years Options exercisable for 10 years from September 14, 2026

Immediate vesting portion 6,000 options One-half of 12,000 options vested on grant date

September 30, 2026 vesting portion 3,000 options One-fourth of 12,000 options vest on September 30, 2026

December 31, 2026 vesting portion 3,000 options One-fourth of 12,000 options vest on December 31, 2026

Indirect common shares held 3,997 shares Common stock held through Spite Family Holdings LP

Key Terms

Stock Options (Right to Buy), exercise price, vesting, indirect ownership

4 terms

Stock Options (Right to Buy) financial

"Security titled "Stock Options (Right to Buy)" was granted to the director"

exercise price financial

"The options have an exercise price of $0.18 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"One-half vested immediately, one-fourth will vest on September 30, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

indirect ownership financial

"3,997 shares of common stock are held indirectly through an affiliate"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Vivos Therapeutics (VVOS) grant to director Gregg C. Johnson?

Vivos Therapeutics granted Gregg C. Johnson 12,000 stock options on September 14, 2026, with an exercise price of $0.18 per share and a 10-year exercisability period from the grant date.

How do the 12,000 VVOS stock options granted to Gregg C. Johnson vest?

Of the 12,000 options, one-half vested immediately on September 14, 2026, one-fourth will vest on September 30, 2026, and one-fourth will vest on December 31, 2026, subject to the grant’s terms.

What is the exercise price and term of Gregg C. Johnson’s VVOS stock options?

The options have an exercise price of $0.18 per share and are exercisable for a period of 10 years from the grant date of September 14, 2026.

How many VVOS options and shares does Gregg C. Johnson hold after this filing?

After the reported grant, Gregg C. Johnson holds 12,000 stock options directly. He also has 3,997 shares of Vivos Therapeutics common stock held indirectly through Spite Family Holdings LP, an affiliate.

Were Gregg C. Johnson’s VVOS transactions under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported for the transactions disclosed for Gregg C. Johnson.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 08:18 PM Accepted by SEC EDGAR 09/18/2026 - 08:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSON GREGG C

(Last) (First) (Middle)

7921 SOUTHPARK PLAZA,

SUITE 210

(Street)

LITTLETON COLORADO 80120

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vivos Therapeutics, Inc. [ VVOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								3,997	I	See footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)(2)	$0.18	09/14/2026		A		12,000		09/14/2026(2)	09/14/2036	Common Stock	12,000	$0	12,000	D

Explanation of Responses:

1. Shares held by Spite Family Holdings LP, an affiliate of the Reporting Person.

2. On September 14, 2026 (the "Grant Date"), the Reporting Person received a grant of 12,000 stock options from the Issuer. One-half vested immediately (and the earliest possible exercise date in Table II relates to this tranche), one-fourth will vest on September 30, 2026 and one-fourth will vest on December 31, 2026. The options are exercisable for a period of 10 years from the Grant Date.

	/s/ Bradford K. Amman as attorney-in-fact for Gregg C. Johnson	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)